Samsung Medical Center: Carcinoma trials

The registry lists 30 Carcinoma studies with Samsung Medical Center as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 2Phase 2 19Phase 3 2Phase 4 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of SorafenibCompletedNCT03163992Phase 2Results posted
• The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With Insulin ResistanceTerminatedNCT04649671Not applicable
• Neoadjuvant Nivolumab for Operable Esophageal CarcinomaStatus unknownNCT03987815Phase 2
• Combination of Nanoxel and Herzuma in Salivary Duct CarcinomaStatus unknownNCT03614364Phase 2
• Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCCStatus unknownNCT03450967Phase 2
• Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal CancerStatus unknownNCT03377400Phase 2
• Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03147404Phase 2
• Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown PrimaryStatus unknownNCT02590055Phase 2
• Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial CarcinomaStatus unknownNCT02535650Phase 2
• Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal LoadStatus unknownNCT02308319Phase 4
• Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT02290977Phase 2
• Diffusion-Weighted Magnetic Resonance ImagingStatus unknownNCT02242786Phase 2
• to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)CompletedNCT02008929Phase 2
• Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor ThrombosisCompletedNCT01911000Phase 2
• Stereotactic Body Radiotherapy for Unresectable Hepatocellular CarcinomaCompletedNCT01910909Not applicable
• Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular CarcinomaCompletedNCT01506115Not applicable
• Genome-wide Association StudyWithdrawnNCT01498757
• Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell CarcinomaCompletedNCT01482520
• Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma PatientsCompletedNCT01481805
• Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell CarcinomaCompletedNCT01474642Phase 2
• Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT01472419
• A Trial of JX-594 in Refractory Colorectal CarcinomaCompletedNCT01469611Phase 1
• Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell CancerCompletedNCT01469598Phase 2
• Study of LV5FU2 Versus FOLFOX for Curatively-resected, Node-positive Esophageal Squamous Cell CarcinomaStatus unknownNCT01467921Phase 2
• A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT01171781Phase 2
• Extent of Central Lymph Node Dissection in Papillary Thyroid MicrocarcinomaStatus unknownNCT01149161Phase 2/3
• Gemcitabine/Oxaliplatin (GEMOX) With or Without Erlotinib (Tarceva) in Advanced Biliary Tract CarcinomaCompletedNCT01149122Phase 3
• Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular CarcinomaCompletedNCT01131689Phase 1
• Sunitinib as Second-line Treatment in Advanced Biliary Tract CarcinomaCompletedNCT01082809Phase 2
• Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT00816634Phase 2